Skip to main content

BASi Announces Expansion into Surgical Models and Medical Devices with Agreement to Purchase Pre-Clinical Research Services

Written by Customer Service on . Posted in Public Companies.

WEST LAFAYETTE, Ind., Nov. 08, 2019 (GLOBE NEWSWIRE) — Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”), a leading provider of nonclinical and analytical contract research services, today announced that the Company has entered into an agreement to purchase substantially all of the assets of Pre-Clinical Research Services, Inc. (“PCRS”), a premier provider of surgical and medical device contract research services.
“We have great respect for the people and services provided by PCRS, and believe the current facilities in Ft. Collins, Colorado, will be an excellent location for future growth,” said Bob Leasure, BASi’s President and Chief Executive Officer. “Our Companies have worked together for several years on multiple projects. Becoming one with PCRS will allow us to provide broader services in more areas of research and development than ever before. The combination will further expand our toxicology business and brings the ability to provide surgical services for pharmaceutical and medical device clients. We believe this addition is perfectly aligned with our strategy of being right-sized; small enough to be flexible and responsive, and comprehensive enough to have meaningful impact on our clients’ product development needs. The facilities and leadership team at PCRS are an excellent complement to our already strong team, and we look forward to working with them to continue to build this team and expand the business in the future.”By combining BASi and PCRS, our clients will have the ability to work with one provider having expertise in a broad range of scientific disciplines, including:PharmacologyToxicologyDrug MetabolismPharmacokineticsBioanalysisIntravascular Device and Structural Heart ModelsSurgical and Medical DevicesScientific and Regulatory ConsultingThe transaction is subject to customary closing processes and is anticipated to close within calendar 2019. A Current Report on Form 8-K containing further details regarding the contemplated transaction has been filed by BASi and is available on the U.S. Securities and Exchange Commission’s EDGAR website.About Bioanalytical Systems, Inc.BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world’s leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. BASi’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit www.BASinc.com for more information about BASi.This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof and various market and operating risks, including those detailed in the Company’s filings with the U.S. Securities and Exchange Commission.FOR MORE INFORMATION:Company Contact:
Jill C. Blumhoff
Chief Financial Officer
Phone: 765.497.8381
jblumhoff@BASinc.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.